These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 7954282)

  • 1. Barriers to clinical trials. Part I: Reimbursement problems.
    Fleming ID
    Cancer; 1994 Nov; 74(9 Suppl):2662-5. PubMed ID: 7954282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reimbursement issues facing patients, providers, and payers.
    Antman K
    Cancer; 1993 Nov; 72(9 Suppl):2842-5. PubMed ID: 8402516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Third-party payers and the cost of biomedical research.
    Iltis AS
    Kennedy Inst Ethics J; 2005 Jun; 15(2):135-60. PubMed ID: 16149205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of clinical trial protocols on patient care systems at the University of Texas M.D. Anderson Cancer Center.
    Huber SL
    Cancer; 1993 Nov; 72(9 Suppl):2824-7. PubMed ID: 8402512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness and reimbursement in patient care.
    Antman KH; Aledort LM; Yarbro J; Wilensky G; Wojcik S; Monaco GP; Windham S
    Semin Hematol; 1989 Jul; 26(3 Suppl 3):32-45. PubMed ID: 2508228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The crisis in clinical cancer research. Third-party insurance and investigational therapy.
    Antman K; Schnipper LE; Frei E
    N Engl J Med; 1988 Jul; 319(1):46-8. PubMed ID: 3288868
    [No Abstract]   [Full Text] [Related]  

  • 7. Medicare reimbursement for clinical trial services: understanding Medicare coverage in establishing a clinical trial budget.
    Barnes M; Korn J
    J Health Law; 2005; 38(4):609-31. PubMed ID: 16673632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Third-party payers and investigational therapy.
    N Engl J Med; 1988 Nov; 319(18):1228. PubMed ID: 3173464
    [No Abstract]   [Full Text] [Related]  

  • 9. Reimbursement issues in cancer clinical trials.
    McKenna RJ
    Cancer; 1990 May; 65(10 Suppl):2405-6. PubMed ID: 2346567
    [No Abstract]   [Full Text] [Related]  

  • 10. Summary of a workshop on the role of third-party payers in clinical trials of new agents.
    Chalmers TC; van den Noort S; Lockshin MD; Waksman BH
    N Engl J Med; 1983 Nov; 309(21):1334-6. PubMed ID: 6633594
    [No Abstract]   [Full Text] [Related]  

  • 11. Anemia trials: lessons for clinicians, politicians, and third-party payers.
    Szczech L
    Kidney Int; 2010 Mar; 77(6):479-80. PubMed ID: 20186158
    [No Abstract]   [Full Text] [Related]  

  • 12. Third party reimbursement for participation in cancer clinical trials: a proposal for legislation.
    Plaue GM
    J Contemp Health Law Policy; 2000; 16(2):305-54. PubMed ID: 10921232
    [No Abstract]   [Full Text] [Related]  

  • 13. Incremental treatment costs in national cancer institute-sponsored clinical trials.
    Goldman DP; Berry SH; McCabe MS; Kilgore ML; Potosky AL; Schoenbaum ML; Schonlau M; Weeks JC; Kaplan R; Escarce JJ
    JAMA; 2003 Jun; 289(22):2970-7. PubMed ID: 12799405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experimental therapy--who shall pay?
    N Engl J Med; 1991 May; 324(18):1291-2. PubMed ID: 2014045
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical trials: are they a good buy?
    Bennett CL; Adams JR; Knox KS; Kelahan AM; Silver SM; Bailes JS
    J Clin Oncol; 2001 Dec; 19(23):4330-9. PubMed ID: 11731516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the financial impact of clinical trials in oncology: results from a pilot study from the Association of American Cancer Institutes/Northwestern University clinical trials costs and charges project.
    Bennett CL; Stinson TJ; Vogel V; Robertson L; Leedy D; O'Brien P; Hobbs J; Sutton T; Ruckdeschel JC; Chirikos TN; Weiner RS; Ramsey MM; Wicha MS
    J Clin Oncol; 2000 Aug; 18(15):2805-10. PubMed ID: 10920127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breakout II. Reimbursement concerns.
    Henney JE; Greene T; Aronson N; Johnson JE; McCabe M; Monaco GP; Poulter CA
    Cancer; 1990 May; 65(10 Suppl):2409-10. PubMed ID: 2334881
    [No Abstract]   [Full Text] [Related]  

  • 18. A Time-Trend Economic Analysis of Cancer Drug Trials.
    Cressman S; Browman GP; Hoch JS; Kovacic L; Peacock SJ
    Oncologist; 2015 Jul; 20(7):729-36. PubMed ID: 26032135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer clinical trials. A case for collaboration.
    Purvis JD
    Cancer; 1990 May; 65(10 Suppl):2391-3. PubMed ID: 2334880
    [No Abstract]   [Full Text] [Related]  

  • 20. Reimbursement for clinical investigation.
    Oldham RK
    Pharos Alpha Omega Alpha Honor Med Soc; 1991; 54(2):33. PubMed ID: 2068219
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.